Crestor is a quite a big molecule for fy17. it is $6b and a growing molecule, They seem confident of doing well here.
They also mentioned in next 2 years there will be about 20 launches of which 5-6 will are very lucrative launches with limited competition.
Besides that, they are hiring a lot of R&D people of around 1000, and increasing the filings. The increased filings will start from q1fy17.
So from fy17, we will see increased filings with increasing complexity of ANDA filed (like cream and ointments and some would that would require clinical trials too) . Oncology green field plant is another positive.
They would also be launching many first timers in india with innovative dosage and combinations ( I think this is ajanta like strategy) and then replicate this india model in brazil.
Tax rate was 36% in 1H and will from fy16 point of view, it will be 25%. so, H2 there will be reduced tax rate.
| Subscribe To Our Free Newsletter |
